TickerFacts.

uniQure N.V. (QURE): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$14.41M
Year ended 2025-12-31
$16.39M
Trailing 12 months to 2026-03-31
-16.1%
5-year compound annual growth
$34.62M2016-12-31: $23.75M2017-12-31: $12.29M2018-12-31: $10.08M2019-12-31: $5.63M2020-12-31: $34.62M2025-12-31: $14.41M$14.41M
2016-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$14.41Mn/a2026-03-02, From 2025-01-01
No annual figure between 2020-12-31 and 2025-12-31.
2020-12-31$34.62M+515.2%2023-02-27, From 2020-01-01
2019-12-31$5.63M-44.2%2022-02-25, From 2019-01-01
2018-12-31$10.08M-18.0%2021-03-01, From 2018-01-01
2017-12-31$12.29M-48.3%2020-03-02, From 2017-01-01
2016-12-31$23.75Mn/a2019-02-28, From 2016-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
uniQure N.V. (QURE)2025-12-31$14.41Mn/a
Pyxis Oncology, Inc. (PYXS)2025-12-31$11.47Mn/a
CV Sciences, Inc. (CVSI)2025-12-31$6.75M-5.8%
Tonix Pharmaceuticals Holding Corp. (TNXP)2025-12-31$6.47M+177.7%
Evofem Biosciences, Inc. (EVFM)2025-12-31$15.57M+0.2%
CASI Pharmaceuticals, Inc. (CASIF)2025-12-31$10.08M-9.6%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$11.60M-25.0%
Jaguar Health, Inc. (JAGX)2025-12-31$7.74M-20.5%
Celularity Inc (CELU)2025-12-31$6.48M-83.5%

Compare QURE, PYXS, CVSI, TNXP side by side · Screen every company in Pharmaceutical Preparations ↗